VPS33A Inhibitors
VPS33A inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of the VPS33A (Vacuolar Protein Sorting 33A) protein. VPS33A is a core component of the HOPS (homotypic fusion and vacuole protein sorting) and CORVET (class C core vacuole/endosome tethering) complexes, which are essential for membrane trafficking processes, particularly in vesicle fusion and cargo sorting in lysosomal and endosomal pathways. VPS33A functions as a tethering factor, facilitating the docking and fusion of vesicles with target membranes, and ensuring proper cargo delivery. This protein plays a vital role in maintaining intracellular trafficking systems, which are necessary for the transport, degradation, and recycling of cellular components. By inhibiting VPS33A, these compounds disrupt key steps in vesicle transport, which can alter cellular processes involving endosomes and lysosomes.
The mechanism of VPS33A inhibitors generally involves binding to functional regions of the protein, preventing its interaction with other components of the HOPS or CORVET complexes. This inhibition interferes with vesicle tethering and fusion, leading to disruptions in the transport and sorting of proteins and other materials within the cell. Researchers use VPS33A inhibitors to investigate the specific roles of this protein in intracellular trafficking, particularly in relation to how it governs endosome-lysosome fusion and other key processes in membrane dynamics. By blocking VPS33A, these inhibitors provide valuable insights into the molecular mechanisms that control vesicle-mediated transport and the maintenance of cellular compartmentalization, contributing to a better understanding of how intracellular transport systems regulate cellular homeostasis and protein turnover.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, could hyperacetylate histones, leading to a condensed chromatin state at the VPS33A gene locus, thus repressing its transcription. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
By inducing DNA demethylation, 5-Azacytidine may specifically reduce transcriptional activity of the VPS33A gene promoter, resulting in decreased VPS33A mRNA levels. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid could selectively downregulate VPS33A gene expression through its interaction with nuclear retinoic acid receptors, which bind retinoic acid response elements in gene promoters. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
Spironolactone may reduce VPS33A gene expression by altering mineralocorticoid receptor-mediated transcriptional programs, leading to secondary effects on vesicle trafficking genes. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $78.00 $260.00 | 18 | |
Hydroxyurea could decrease VPS33A expression by inhibiting ribonucleotide reductase, thus reducing deoxyribonucleotide pools and causing a retardation of the cell cycle, indirectly affecting gene expression. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate might decrease VPS33A mRNA synthesis by inhibiting dihydrofolate reductase, leading to a depletion of nucleotide precursors required for DNA and RNA synthesis. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate could suppress VPS33A gene transcription by inhibiting histone deacetylation, which would increase histone acetylation and potentially close off the chromatin region encompassing the VPS33A gene. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine might reduce expression of VPS33A by disrupting endosomal and lysosomal acidification, which is crucial for vesicular trafficking pathways that are closely linked to the function of VPS33A. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 could lead to a reduction in VPS33A expression as a response to its inhibition of vacuolar-type H+-ATPase and subsequent disruption of autophagic and endocytic vesicular pathways. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride may downregulate VPS33A expression through the inhibition of GSK-3, which might change the phosphorylation status of transcription factors controlling VPS33A gene transcription. | ||||||